San Diego-dependent Viking Therapeutics marked itself as a serious competitor from the weight loss drug marketplace in February soon after revealing promising info from a mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when specified for a weekly injection As well as in March the compa